These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38289126)

  • 1. NT5DC2 knockdown suppresses progression, glycolysis, and neuropathic pain in triple-negative breast cancer by blocking the EGFR pathway.
    Sang R; Yu X; Xia H; Qian X; Yong J; Xu Y; Sun Y; Yao Y; Zhou J; Zhuo S
    Mol Carcinog; 2024 Apr; 63(4):785-796. PubMed ID: 38289126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling.
    Qiao L; Dong C; Jia W; Ma B
    Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
    Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
    J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
    Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
    Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma.
    Li KS; Zhu XD; Liu HD; Zhang SZ; Li XL; Xiao N; Liu XF; Xu B; Lei M; Zhang YY; Shi WK; Cao MQ; Xu YF; Tang ZY; Sun HC
    Cell Death Dis; 2020 May; 11(5):335. PubMed ID: 32382041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
    Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
    Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circ-CSNK1G1 promotes cell proliferation, migration, invasion and glycolysis metabolism during triple-negative breast cancer progression by modulating the miR-28-5p/LDHA pathway.
    Zan X; Li W; Wang G; Yuan J; Ai Y; Huang J; Li Z
    Reprod Biol Endocrinol; 2022 Sep; 20(1):138. PubMed ID: 36109751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NT5DC2 knockdown inhibits colorectal carcinoma progression by repressing metastasis, angiogenesis and tumor-associated macrophage recruitment: A mechanism involving VEGF signaling.
    Zhu Z; Hou Q; Guo H
    Exp Cell Res; 2020 Dec; 397(1):112311. PubMed ID: 32991874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
    Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
    FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CircWHSC1 regulates malignancy and glycolysis by the miR-212-5p/AKT3 pathway in triple-negative breast cancer.
    Ding L; Xie Z
    Exp Mol Pathol; 2021 Dec; 123():104704. PubMed ID: 34624276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
    Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity.
    Liu H; Ertay A; Peng P; Li J; Liu D; Xiong H; Zou Y; Qiu H; Hancock D; Yuan X; Huang WC; Ewing RM; Downward J; Wang Y
    Mol Oncol; 2019 Sep; 13(9):1874-1886. PubMed ID: 31199048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
    Wang JJ; Zou JX; Wang H; Duan ZJ; Wang HB; Chen P; Liu PQ; Xu JZ; Chen HW
    Acta Pharmacol Sin; 2019 Aug; 40(8):1067-1075. PubMed ID: 30670815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential.
    Pelicano H; Zhang W; Liu J; Hammoudi N; Dai J; Xu RH; Pusztai L; Huang P
    Breast Cancer Res; 2014 Sep; 16(5):434. PubMed ID: 25209360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression.
    Bi J; Wu Z; Zhang X; Zeng T; Dai W; Qiu N; Xu M; Qiao Y; Ke L; Zhao J; Cao X; Lin Q; Chen XL; Xie L; Ouyang Z; Guo J; Zheng L; Ma C; Guo S; Chen K; Mo W; Fu G; Zhao TJ; Wang HR
    Nat Commun; 2023 Apr; 14(1):2342. PubMed ID: 37095176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect.
    Shi Y; Zhang Y; Ran F; Liu J; Lin J; Hao X; Ding L; Ye Q
    Cancer Lett; 2020 Dec; 495():53-65. PubMed ID: 32946964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.